2024

1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

   Cancers, Vol. 16, Núm. 9

2. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

   Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

3. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

   Cancers, Vol. 16, Núm. 2

4. Cancer-Stem-Cell Phenotype-Guided Discovery of a Microbiota-Inspired Synthetic Compound Targeting NPM1 for Leukemia

   JACS Au, Vol. 4, Núm. 5, pp. 1786-1800

5. Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma

   HemaSphere, Vol. 8, Núm. 7

6. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

   Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

7. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma

   Leukemia and Lymphoma, Vol. 65, Núm. 3, pp. 323-332

8. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

   The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

9. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

   Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

10. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges

    Frontiers in Immunology, Vol. 15

11. Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

    Microscopy and Microanalysis, Vol. 30, Núm. 1, pp. 151-159

12. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

13. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

    Science translational medicine, Vol. 16, Núm. 734, pp. eadg7962

14. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

15. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

    Annals of Hematology

16. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

    eClinicalMedicine, Vol. 73

17. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714

18. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

19. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

    Leukemia, Vol. 38, Núm. 9, pp. 1985-1991

20. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

    Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461